Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Valneva SE

A Month After Lung Cancer Withdrawal, Takeda Gets Approval For New Colorectal Cancer Drug

The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.

Approvals Cancer

Durect Eyes Phase III In Alcoholic Hepatitis Despite Phase IIb Miss

Durect thinks its epigenetic modulator shows promise with data showing reduction in 90-day mortality despite missing the primary endpoint of mortality and liver transplant rate.

Clinical Trials Business Strategies

Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets

Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.

Deal Watch Business Strategies

Emerging From Stealth Mode, Tesselate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs

As investment and interest grows in synthetic lethality cancer treatments, Netherlands-headquartered Tesselate Bio hopes to expand horizons within the field by hitting the novel FANCM target and developing its own companion diagnostic.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • BliNK Biomedical SAS
    • Crucell Sweden AB
    • Iomai Corporation
    • Intercell USA, Inc.
    • Intercell AG, Vivalis
UsernamePublicRestriction

Register